jfs2152

Wall Street is Short VBIV, but I'm Long *Target: [$3.50]*

Long
jfs2152 Updated   
NASDAQ:VBIV   VBI Vaccines, Inc.
Link to Culper Research report that states they are shorting VBIV because the company is "worthless"
img1.wsimg.com/...IV_6-2-2020.pdf?ver=159110...

First, it's always important to consider ALL information. It's also important to be transparent about knowledge. If you are going to make any VBIV trades you really should read the entire report.

1) I think many of the points made in the Culper Report are legitimate
2) I am not as optimistic about long term price targets as those seen at Guggenheim and on yahoo finance
3) I still believe this is a good short-term trade based on sentiment and momentum regarding June 22-24 release of clinical glioblastoma data

Stop loss @ $2.04
Trade closed: target reached:
Closed trade at $2.41 today

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.